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POLICY
The changing landscape of genetic testing and its
impact on clinical and laboratory services and research
in Europe
Ros Hastings*,1, Guido de Wert2,3, Brian Fowler4, Michael Krawczak5, Eric Vermeulen3,6, Egbert Bakker7,
Pascal Borry8, Wybo Dondorp2, Niels Nijsingh2, David Barton9, Jörg Schmidtke10, Carla G van El3,6,
Joris Vermeesch11, Yrrah Stol12, Heidi Carmen Howard13 and Martina C Cornel3,6
The arrival of new genetic technologies that allow efficient examination of the whole human genome (microarray, next-
generation sequencing) will impact upon both laboratories (cytogenetic and molecular genetics in the first instance) and
clinical/medical genetic services. The interpretation of analytical results in terms of their clinical relevance and the predicted
health status poses a challenge to both laboratory and clinical geneticists, due to the wealth and complexity of the information
obtained. There is a need to discuss how to best restructure the genetic services logistically and to determine the clinical utility
of genetic testing so that patients can receive appropriate advice and genetic testing. To weigh up the questions and challenges
of the new genetic technologies, the European Society of Human Genetics (ESHG) held a series of workshops on 10 June 2010
in Gothenburg. This was part of an ESHG satellite symposium on the ‘Changing landscape of genetic testing’, co-organized by
the ESHG Genetic Services Quality and Public and Professional Policy Committees. The audience consisted of a mix of
geneticists, ethicists, social scientists and lawyers. In this paper, we summarize the discussions during the workshops and
present some of the identified ways forward to improve and adapt the genetic services so that patients receive accurate and
relevant information. This paper covers ethics, clinical utility, primary care, genetic services and the blurring boundaries
between healthcare and research.
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The application of the new genetic technologies that allow efficient
examination of the whole human genome (microarray, next-genera-
tion sequencing (NGS)) will impact upon both laboratories (cyto-
genetic and molecular genetics in the first instance) and clinical/
medical genetic services. The high resolution of these technologies will
help clinical geneticists to diagnose more cases than before. However,
the implementation raises challenges that need to be addressed to
safeguard a scientifically robust, ethically sound and socially accep-
table level of service provision. The interpretation of the results in
terms of their clinical relevance and the predicted health status poses a
challenge due to the wealth and complexity of the information
obtained. Clinicians need to decide how much information should be
given to patients, (1) related to the symptoms they were referred for,
(2) on other information of immediate health consequences, (3) on
the carrier status of autosomal recessive conditions and (4) on
variants of uncertain nature. Laboratory experts (and bioinformati-
cians) need to interpret the significance of the results for the clinician,
and take responsibility for what they do or do not report. With the
cytogenetic and molecular genetic service technologies merging closer,
perhaps now is also the time to provide an integrated lab service.
Where incidental (ie, unsought or unexpected) findings concern
currently unknown variants, common databases need to be developed
to collect the evidence that becomes available. This evidence needs to
be structured to form a suitable basis for evidence-based medicine.
There will be an increased workload for diagnostic labs and an
increased complexity of cases requiring interpretation. Moreover,
clinical genetic services will need to expand or differentiate their
services to cope with the increased complexity of cases and volume of
work.
High-throughput technologies are rapidly changing the field of
genetic screening. The ethical and policy challenges of large-scale
applications in healthy individuals, for instance in newborn screening,
need to be discussed. These new technologies also have the potential
to detect every known genetic disease even before symptoms occur.
Their responsible implementation has an impact on training, which
should prepare health workers to decide and discuss when these
technologies are or are not appropriate for certain medical indica-
tions. The relevance of the results in terms of sensitivity and
predictive value needs to be evaluated. A central criterion to decide
whether or not tests should be offered in regular health care is the
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clinical utility, that is: whether the test will lead to an improved
outcome.1 Guidelines for referral to clinical genetic services may need
to be updated. Accreditation of services may need revision, or self-
regulation could be appropriate.
It is important to know what the patient expects and/or needs.
Who owns the whole-genome information and who decides what is
relevant for the patient to know? Who decides on disclosure of genetic
information to the patient—everything or selective? What are the
risks of giving too much information, or not enough? What
protection should there be for the patient? What should the
healthcare system offer? The public at large must be informed on
pros and cons of testing. And what will be the impact on clinical
services of private companies offering genetic testing for multifactorial
diseases through the internet? Biobanks and clinical services are
merging closer. What does that mean for regulation, re-contacting
and informed decision making?
To discuss the questions and challenges of new genetic technolo-
gies, the European Society of Human Genetics (ESHG) held a satellite
symposium on the ‘Changing landscape of genetic testing’, co-
organized by the ESHG Genetic Services Quality and Public and
Professional Policy Committees and co-funded by the Netherlands
Centre for Society and Genomics and Centre for Medical Systems
Biology. The audience consisted of a mix of laboratory geneticists,
clinical geneticists, ethicists, social scientists, patient organization
representatives and lawyers.
In this paper, we summarize the discussions from the workshops
and present some of the potential ways forward to improve and adapt
the genetic services so that patients can receive accurate and relevant
information. This paper covers ethics, clinical utility, primary care,
genetic services and the blurring boundaries between healthcare and
research.
ETHICS: SEQUENCING VS ANALYSIS
The NGS and whole-genome analysis (WGA) are rapidly becoming
cheaper, making it affordable for clinical, research and screening
purposes. Although it remains unclear what hopes are realistic, it is
conceivable that we might attain the possibility of personalized medicine:
prevention, diagnosis and treatment tailored to the individual’s genome.
It is often assumed that NGS automatically results in WGA and
that the two are more or less identical. The analysis performed after
NGS may, however, still be targeted. Whether one performs a WGA
instead of a targeted analysis (using filters to analyze only a selected
part of the genome, such as all genes known to be related to a disease)
is a choice that needs to be justified.
DIAGNOSIS VS SCREENING
When a clinically motivated WGA regularly produces results that have
no direct relation to the initial problem and phenotype of the patient,
and these results are communicated, is this part of the diagnostic
practice, or is it a form of screening? Obviously, traditional demarcation
lines between diagnostic testing and screening are under pressure—the
distinction between these forms of testing seems to be blurring. It was
suggested that diagnostics can be distinguished from screening by its
starting point: a clinical problem and/or a phenotype. Diagnosis is
centred around the attempt to locate the cause of a specific medical
problem. WGA may also generate ‘incidental findings’.
INCIDENTAL FINDINGS, ADDITIONAL OR UNSOLICITED
INFORMATION
The terms ‘unexpected’ or ‘incidental findings’ are in themselves
misleading, as it is a matter of statistics if and when a certain result
will occur. It was suggested that perhaps the term ‘additional
information’ or ‘unsolicited information’ is more appropriate.
In the diagnostic context, standard tests for particular clinical
problems may produce additional results that were not sought. In
discussing the implications of this phenomenon, it is important to
keep in mind the distinction between targeted and WGA. The
importance of using filters was acknowledged: a clinical test should
address a particular clinical problem (eg, in case of a family history of
breast cancer at a young age looking at breast cancer genes only; or
one step further: not reporting mutations known to be non-
pathogenic mutations). For some conditions, however, particularly
unexplained intellectual disability, WGA is the only option as it is not
possible to narrow down the scope of analysis by means of filters,
therefore the analysis has to be non-targeted.
Generic consent
How do you involve the patient in the choice of whether and what
unsolicited information should be disclosed? If a ‘generic consent’
approach is used, what sort of information should be supplied before
asking a patient to consent to WGA? Can this information be
satisfactorily framed into broader categories of possible outcomes?
Would this approach satisfy the existing norms of consent? Obviously
the availability of unsolicited information, that may physically and/or
mentally harm the client—or his relatives, can lead to serious
dilemmas particularly if a patient waives his right to know.
Retention and recontacting
What should be done with the huge amount of sequence data of a
given patient, should it be stored for later use as required by current
diagnostic guidelines (eg, future clinical questions or also for
pharmacogenomics) or should one re-sequence the sample upon
request? Clinical genetic centers may have most expertise, primary
care physicians might perhaps not be the most obvious ‘librarians’ of
patients’ genomic information. An alternative could be to give the
results to the patient, who then has discretion over what to do with
them. Similarly to the storage of body tissues, there should always be
a possibility to opt out of retention. Companies might offer to store
and update information. Whether storage or re-sequencing is done
depends on the cost of sequencing vs the cost of storage. Data storage
will require a legal framework to cover ethical questions, which might
differ from country to country. When sequencing becomes cheaper,
the majority of the participants supported the idea that in a clinical
situation re-sequencing is the safest option.
Should the patient be recontacted when new or more information
becomes available as a result of scientific progress, and if so, under
what conditions? It would be both unsound and unpractical to
propose a general duty to recontact, but at least within an existing
treatment relationship, the doctor has a prima facie duty to inform
his patient about findings which are relevant to him. But what is
relevant? Many situations will, unfortunately, not be so clear-cut. An
additional complication is when interests of third parties are at
stake—here one may think of family members or of persons with a
particular professional responsibility for the safety of others, such as
air pilots.
Newborn screening and prenatal uses
It seemed clear to most participants that evidence is currently lacking
for making WGA a sensible approach for newborn screening. The
advantages are slim and there may be real disadvantages. International
guidelines emphasize the child’s right not to know, that is, their right
to later decide about testing themselves. A related matter is the
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question as to whether parents should be prevented or discouraged
from satisfying their ‘curiosity’ by means of direct-to-consumer
(DTC) tests although a targeted analysis of a selection of disorders
that pass the current criteria for screening would be wise.
In the case of prenatal testing, matters are even more complex.
Collaboration between gynecologists and geneticists is essential.
Interestingly, there was a slight difference between the ‘American
view’ and the ‘European view’. Whereas the first emphasizes the easy
availability of new technologies and the choice of the individual
pregnant woman, Europeans seemed more reluctant with regard to
providing such choices without good reason. It was stressed that
pregnancy is a time of great anxiety and that unclear results cause
distress to women. Also, there were concerns of a possible informa-
tion overload and the complexity of the choices under time
constraints. In the workshop, the prenatal diagnosis discussions did
not centre on the issue of abortion, instead it centred on the problems
concerning the (future) child’s right not to know. The resemblance
between WGA prenatal testing and WGA in newborns indicates a
blurring of the distinction between reproductive and non-reproduc-
tive screening.
The workshop emphasized the importance of clarity, validity,
evidence-based practice and ethical reflection.
CLINICAL UTILITY
The question of how to build the evidence for the clinical utility of
genetic tests exploiting high-throughput DNA sequencing technolo-
gies was discussed. The current standards for the implementation and
provision of diagnostic services in health care are laid down, for
example, in the ACCE framework,1 assessing analytic validity, clinical
validity, clinical utility and ethical, legal and societal issues. New
technologies could only change ‘the landscape of genetic testing’ if
their clinical utility is clear. Clinical utility can scarcely be assessed in a
purely academic setting, and for many rare diseases, clinical trials may
not be feasible. The evidence must be built in clinical practice
otherwise, sufficient data necessary to judge the impact upon the
individual patient and their family made by the technology, and by
the genetic variants newly detected with it, would often not be
available.
At present, any reliable assessment of the clinical utility of new
technologies for genetic testing is premature as the necessary data are
not currently available. Moreover, before individual test results can be
communicated to patients, the clinical validity of the data needs to be
proven. Although it may be possible for a test to have clinical utility
without having much clinical validity, this is rather unlikely to be the
case for the (newly detected) genetic variants because, almost by
definition, their clinical relevance will be unclear at the time they are
first detected. Anyhow, in view of the apparent idiosyncrasies of the
new sequence-based genetic tests, five key aspects should be con-
sidered before building up any evidence for their clinical validity or
utility could be regarded a sensible option.
Is building up the evidence worth the effort in the first place?
Media attention in combination with economic interests may well
serve to generate a (perceived) demand for sequence-based genetic tests,
even if such tests were met with scientific scepticism.2 Furthermore,
although the predictive value of the (mostly incidental) genetic
findings is currently unclear, the data may become scientifically
useful in the future. On the other hand, if the effect size of newly
detected variants that are sufficiently frequent to allow systematic
follow-up is as low as suggested, for example, by recent genome-
wide association studies (GWAS3), then their clinical evaluation will
be both unproductive and unrewarding. Moreover, it remains to be
seen whether the target population of sequence-based genetic tests,
which will mostly be families with single-gene disorders, would be
interested in participating in the extensive follow-up programmes
required.
Does building up the evidence seem feasible?
In the present context, it appears mandatory that the quality and the
level of detail of the phenotypes match the richness of the genotype
data. This is because, contrary to common belief, reliable genotype–
phenotype relationships can only be established in retrospective
manner if the phenotype is sufficiently specific for the genotype,
and not vice versa.4 Moreover, the phenotype specificity of the
genotype will likely vary between phenotypes (eg, a common
disorder such as diabetes vs diabetes at a young age in a family
with an autosomal dominant inheritance pattern). Finally, as most of
the required phenotypic data will have to come from clinical routine,
their depth and quality will also be determined by the respective
health care setting. Therefore, the feasibility of obtaining sufficient
evidence for the clinical validity of a given genetic test will depend
very much upon the test itself and on the clinical context in which it
is provided.
What is the advantage of building up the evidence in a clinical
context?
Based on the experience from GWAS of common disease, it appears
likely that, in most instances, only rare genetic variants will have
sufficiently strong phenotypic effects for them to warrant clinical
follow-up.5 On the other hand, rarity implies that the clinical validity
of diagnostic tests for such variants can only be assessed by studying
the co-inheritance of genotypes and phenotypes in families. If it turns
out that the quality of data obtained in a clinical context is
insufficient and does not match the standards of common scientific
practice, then additional efforts will have to be made, for example,
through the establishment of systematic and standardized clinical
assessment protocols.
For which type of diseases will building up the evidence be
primarily beneficial?
Clinical validity and clinical utility can only be expected to be
high for the genetic diagnoses of ‘simple’ single-gene disorders.
Evidence for the clinical validity of newly detected, mostly rare
genetic variants is likely to come from family studies, and for
a variant to show familial aggregation, its penetrance must be
high. As the initial target population of sequence-based tests
will comprise families with single-gene disorders, the volume of
accidentally detected genetic associations with common disease is
likely to be rather small.
If the evidence were to be built up, who should drive the action?
As any sensible assessment of clinical validity and utility will be
confined initially to single-gene disorders, and then proceed in a
clinical context, efforts in this direction would best be initiated and
coordinated by disease-specific networks. The role of academia will
depend on the extent to which research and health care infrastruc-
tures are intertwined. Concerted international efforts will be required
for any endeavours to establish sequence-based tests as a means of
routine genetic testing to be successful. Finally, individuals facing
reproductive decision making may become ‘captivated’ by, and
primed for such tests by commercial offers, including DTC carrier
and prenatal diagnosis.6
The changing landscape of genetic testing
R Hastings et al
913
European Journal of Human Genetics
PRIMARY HEALTH CARE SERVICES
Incorporating the available genomics knowledge into primary care has
proven to be difficult. Clinical genetics services are adequately
developed, but only few questions of well-informed patients on
serious disorders reach these specialized centres. The introduction of
whole-genome testing, may prove even more challenging for health
care as a whole, and for primary care in particular. However, as
almost any health problem nowadays has a genetic component,
reflection is needed on possibilities, prerequisites and barriers for
incorporating genetics/genomics for general practice, occupational
medicine and public health.
How far do we want to go in assessing and preventing risk? Should
the genomes of the whole population be sequenced? Or could
determining relevant biomarkers at different moments in life be more
useful?
What is necessary for incorporation of NGS in primary care?
Currently, many general practitioners have difficulties in adequately
stratifying genetic risk and knowing when to refer patients. Also,
knowledge is lacking to address questions from patients based on
DTC genetic testing, although rarely encountered. The European
Medicines Agency could be an important stakeholder on the
European level if, similar to the USA Food and Drug Administration,
it could decide whether a test is analytically and clinically valid. In the
United Kingdom, the National Health Service identifies useful and
cost-effective applications. GPs’ time and knowledge constraints
might be met by recent developments, such as the creation of
‘primary care GP super clinics’, as planned in the Australia, by
embedding a genetic counselor in primary care. Genetics needs to be
‘normalized’ in both the general public and (primary) care; fears and
myths need to be addressed. Apart from different professional (eg,
clinical chemists, clinical geneticists and medical specialists) and
health care bodies and government agencies (eg, the EU Directorate
General for Health and Consumer Affairs), the general public is
important for risk assessment aiming to prevent disease. Needs and
wishes of public and the primary care professionals must be met.
Whereas patient organizations have an established role as stakeholder,
there is no equivalent format for ‘healthy’ people beside perhaps
consumer organizations.
The role of stakeholders and organizations
Realistically speaking genetic knowledge is applied only when it
is integrated in guidelines and financed by health insurance. Primary
care could pilot projects to determine how genetics can be incorpo-
rated in the field. More is expected from supranational organizations,
such as the provision of guidelines and the establishment of registries
to create clarity about genetics applications in primary care. It is
important to stimulate dialog and collaboration between geneticists,
different professional societies and public health organizations,
especially regarding population screening. Bridges need to be built
because early specialization in university curricula often hinders
communication between these different professional domains. In the
case of screening programs, evaluation should be in place to ensure
the population is not harmed. For DTC testing, post-marketing
surveillance should be organized, preferably by independent institu-
tions and/or researchers. As commercial parties are here to stay,
collaboration may be better than exclusion. Self-regulation is
preferred to legal guidance because national and supranational laws
are outdated by the time they finally become legal code. Laws also
cannot prevent genetic practices that work across borders, such as
commercial testing.
GENETIC SERVICES
Routine genetic diagnostics is starting to use NGS and it will generate
data/information not necessarily related to the indication but could
be used for other health care purposes (screening, diagnosis and
personalized medicine). Expertise teams for medical genomics or
clinical geneticists could upon request discuss the ‘screening’ results
and the wider implications of the results for the patient and give
health advice based on the genome data generated. This will bring a
substantial change in the scope for clinical geneticists and will need
training programs for professionals and public. For research projects,
one would need more specific consent forms and an agreement about
the data usage and storage (anonymous or coded).
The challenges of NGS from a laboratory perspective will be the
identification of new syndromes/genetic diseases as well as ‘normal
variants’ lacking clinical significance. This will require that all genetic
laboratories interpret the clinical significance of the information
obtained.
How can we best restructure laboratory services and determine
and interpret data/information that should be made available
to clinicians?
A core analytical facility is envisaged that would service the various
genetic disciplines. This facility should guarantee the maintenance of
best-quality standards given the present analytical limitations and the
built-in error rate using external quality control. Mechanisms should
be installed to exclude mix up of samples. In this vision, the local
speciality laboratory (molecular/cytogenetics/biochemical genetics)
might undertake confirmatory and repeat testing if needed, select
information from the NGS data according to the clinical question,
and arrange or perform additional tests as and when needed. In order
to fulfill this function, there is need for freely available patient
databases/comprehensive data on all known mutations and detailed
documentation of clinical disease and non-disease associations.
Massive bioinformatics systems and optimal interaction between the
laboratory and the clinician are crucial.
Should all genetic referrals be offered NGS or are there exceptions
with a targeted approach, for example, prenatal testing?
As long as targeted testing is better and cheaper, this is preferred,
however, in the future NGS is a realistic scenario. It was not
considered appropriate for prenatal diagnosis. It could be that NGS
is eventually very cost effective and easy to perform and may provide
helpful information about confounder traits in monogenetic disorders
that this technology becomes the first and main option. The analysis
performed after NGS may, however, be targeted using filters.
It was considered that, in general, genetic reports should be
restricted to the clinical question but there may well be certain
specific disease-related genotypes that should be disclosed in the
interest of the patient, but clear consensus guidelines will be needed
for this. There might be different disclosure levels related to the
clinical presentation, potential outcome changes (treatment) and
particular patient-related factors. There is also a need to protect
laboratory workers in those situations where a potential dilemma
regarding disclosure exists, for example, when lab results reveal an
incestuous relationship.
Amalgamation of the cytogenetics and molecular genetic disciplines
into genomic services was broadly supported, integrated with proteo-
mics and metabolomics services. Also pharmacogenetics fits within this
structure. Specialist training remains needed given the expected massive
increase of the scientific and technical knowledge base. A generic
component of training seems inevitable especially for molecular and
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cytogenetics (as has been started in the UK and The Netherlands).
New disciplines will be needed, for example, genome informatics.
BLURRING OF BOUNDARIES BETWEEN RESEARCH AND
CLINICAL GENETIC TESTING SERVICES
The goal of research is the generation of new evidence and knowledge,
and that of clinical care to endorse patients’ best interests. Although
in theory this distinction may appear clear, in practice the division
between both contexts is in fact ambiguous.7,8 For example, it is not
always easy for patients to distinguish genetic tests that are offered as
a part of their clinical management from tests that are offered as a
part of a research protocol.9,10 Studies also show that some
researchers are likely to be seen, and see their own research
activities, as a way of providing care.11 Finally, DTC genetic testing
blurs many boundaries; between consumers and patients as well as
between consumers and research subjects.
Previous research has highlighted the various concerns that
accompany the blurring of boundaries between research and genetic
testing services.8,12 Is the informed consent procedure adequate? Do
patients have a sufficient understanding of what is happening to the
sample they provide and what the potential implications are as a
consequence of their participation in the research study? Given this
understanding, or lack thereof, is their participation voluntary?
Moreover, could pressure arise when the question to participate in
research is being asked by a treating healthcare professional.
Interestingly, it was also reported that some research activities are
re-classified as non-research activities in order to avoid the
requirements linked to ethical approval of their research.12 During
the workshop, two different case scenarios were discussed.
Case 1: DTC genetic testing companies
The first scenario made reference to a particular DTC genetic testing
company, which offers whole-genome testing. Consumers can order
various genetic testing packages through the company’s websites
(ie, for genealogy purposes, health purposes or both). By signing the
company’s consent form for the genetic testing services, consumers
also agree that their genetic and other contributed personal infor-
mation will be stored in the company’s research databases, and
authorized company personnel will conduct research using said
databases. Is blurring between a consumer purchasing the genetic
test and being part of research taking place in this context? Workshop
participants voiced concerns about a blurring between health promo-
tion and health care. Although the information provided might make
people reflect over genetic and environmental factors that influence
their health, it does not meet the standards of clinical validity and
utility and companies usually have disclaimers stating that their
services are not intended to be diagnostic services. That being said,
companies also make many health-related claims on their websites
and it has been documented that some consumers do not understand
this.13 Furthermore, consumers may overvalue the predictive
character of the information they receive. Consequently, discussion
arose about the difference between information provision and
interpretation. Providing a huge amount of information will be
increasingly possible in genetics, but workshop participants wondered
who will interpret the data and how will this be done?
Informed consent
There is a lack of differentiation between the informed consent
procedure for the purchasing of a genetic test and for the research
that is performed using consumers’ data. Consumers might not be
sufficiently informed about the (particular forms of) research
activities to make an informed choice. For example, it was
documented that some research participants would not want to
participate in studies of homosexuality. Many may have problems
with the commercial practices that could follow from the research
activities. Through the research activities of DTC companies,
consumers are becoming research participants and are, in fact,
paying to participate in research.
Privacy and confidentiality
Confidentiality and anonymity have become important standards in
genetic research. However, this might be challenged more and more
in the future, for instance when consumers/research participants
of DTC companies share their results with others through online
communities. Some genetic research, although anonymised, might
create group harm in certain communities.
Case 2: longitudinal multigeneration research
The second case scenario is a Dutch research cohort study (http://
www.lifelines.net): a triple generation longitudinal population-based
study among 165 000 inhabitants of the northern Netherlands to
study genetic and environmental risk factors for prevalent multi-
factorial disorders. All research participants receive questionnaires
and a basic medical examination. The computerized patient files
of the GPs are the main source for follow-up. The research study
provides the GPs of research participants with the results of the
medical tests. Again anonymity is at stake: is a guarantee of privacy
still possible when data are collected from three generations in a
certain delimited geographical region? Return of the results needs
to be discussed: should that go further than the basic medical
examinations?
The blurring of boundaries between research and genetic testing
services generates a need for more policy development on issues
concerning anonymity, privacy, confidentiality, ownership, return of
results and informed consent in both the research and clinical realms.
CONCLUSIONS
The workshop identified the following priorities for further policy
development:
 Professionals from laboratory and clinic as well as patients, ethicists
and social scientists need to collaborate to develop policy in the
changing landscape of genetic testing.
 Techniques investigating the whole genome will generate additional
findings: ‘always expect the unexpected’. Before starting to use these
techniques a policy on ‘unsolicited findings’ must be defined.
 When sequencing becomes cheaper the re-sequencing of a patients
DNA, as opposed to storing the original data, is likely to be the
safest option provided the latter is not a requirement by guidelines.
 Generic consent should be obtained for WGA/NGS.
 Generic training programmes for laboratory and clinical staff
(including GPs) will need to evolve that incorporate these new
technologies as disciplines merge.
 A core analytical facility is envisaged that would service the various
genetic disciplines.
 Ethical, legal and social issues must be addressed in tandem with
scientific and technological progress.
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